NCT02015117
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Radiation therapy, Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor, Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: 
Exclusions: Patients with known leptomeningeal metastases; Patients with prior radiation therapy to the whole brain (prior stereotactic radiosurgery allowed)
https://ClinicalTrials.gov/show/NCT02015117